Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:52:52 2024-03-28 pm EDT 5-day change 1st Jan Change
5.53 USD -25.77% Intraday chart for Kodiak Sciences Inc. -4.34% +81.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss MT
Kodiak Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Kodiak Sciences Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
UBS Trims Kodiak Sciences Price Target to $3 From $4, Maintains Neutral Rating MT
Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from NASDAQ Biotechnology Index CI
North American Morning Briefing : All Eyes on -2- DJ
North American Morning Briefing : Stocks Futures -2- DJ
Kodiak Sciences' Q3 Loss Narrows MT
Kodiak Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care MT
Kodiak Sciences Share Fall; Company to Resume Tarcocimab Tedromer Eye Drug Development Program MT
Kodiak Sciences Inc. Announces Phase 3 Glow Superiority Study Evaluating Tarcocimab Tedromer 5 Mg in Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy CI
Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting CI
European Midday Briefing : Geopolitical Risks Continue to Drag on Stocks DJ
Lonza Shares Drop After Warning of 2024 Profitability Shortfall DJ
Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue DJ
Lonza cuts 2024 margin target again after CEO departure RE
Transcript : Kodiak Sciences Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 12:55 PM
Sector Update: Health Care Stocks Gain Premarket Thursday MT
Kodiak Sciences Says Tarcocimab Tedromer Showed 'Matched Efficacy' Versus Aflibercept in Eye Disease Phase 3 Trial MT
Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study CI
North American Morning Briefing : Focus Shifts to -2- DJ
Kodiak Sciences Chief Medical Officer Steps Down MT
Chart Kodiak Sciences Inc.
More charts
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a technology platform for retinal medicines. The Company is engaged in preventing and treating the major causes of blindness by developing and commercializing next-generation therapeutics for chronic, high-prevalence retinal diseases. The Company's ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company's product candidate, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its KSI-501 is a dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
7.45 USD
Average target price
3.5 USD
Spread / Average Target
-53.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Kodiak Sciences Inc. - Nasdaq
  4. News Kodiak Sciences Inc.
  5. Update: Kodiak Sciences Prices $560.9 Million Public Share Offering; Shares Up 21% Wednesday